Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.55M | 1.49M | 754.40K | 15.73M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.55M | 1.49M | 754.40K | 15.73M | 2.00M |
| Cost of Revenue | 2.26M | 3.61M | 3.33M | 2.81M | 1.44M |
| Gross Profit | 23.28M | -2.12M | -2.57M | 12.93M | 556.20K |
| SG&A Expenses | 6.78M | 7.29M | 6.67M | 6.56M | 5.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.77M | 30.81M | 23.87M | 21.00M | 8.19M |
| Operating Income | 6.77M | -29.33M | -23.11M | -5.27M | -6.19M |
| Income Before Tax | 19.34M | -39.25M | -22.00M | -4.27M | -8.25M |
| Income Tax Expenses | 9.00M | -4.09M | -2.37M | -1.89M | 9.22M |
| Earnings from Continuing Operations | 10.34M | -35.15M | -19.63M | -2.38M | -17.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.34M | -35.15M | -19.63M | -2.38M | -17.47M |
| EBIT | 6.77M | -29.33M | -23.11M | -5.27M | -6.19M |
| EBITDA | 6.92M | -29.18M | -22.96M | -5.12M | -6.05M |
| EPS Basic | 0.66 | -2.24 | -1.26 | -0.16 | -1.35 |
| Normalized Basic EPS | 0.26 | -0.52 | -0.29 | -0.06 | -0.13 |
| EPS Diluted | 0.66 | -2.24 | -1.26 | -0.16 | -1.35 |
| Normalized Diluted EPS | 0.26 | -0.52 | -0.29 | -0.06 | -0.13 |
| Average Basic Shares Outstanding | 47.23M | 47.07M | 46.74M | 43.96M | 38.92M |
| Average Diluted Shares Outstanding | 15.74M | 15.69M | 15.58M | 14.65M | 12.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |